BC Extra | Dec 16, 2019
Financial News

Immuneering to bolster cancer pipeline, expand services unit with $17M series A

Eleven-year-old Immuneering Corp. has raised its first venture round as it gears up to send its inaugural program to the clinic to treat cachexia in cancer patients and extensively expand its pipeline. Some of the...
BC Innovations | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | Sep 27, 2019
Product Development

Lessons from Healey ALS on how to build platform trials quickly

The first ever platform trial in ALS provides a recipe for getting these collaborative studies off the ground quickly and with early buy-in from companies. Platform trials take advantage of a master protocol to test...
BC Extra | Sep 23, 2019
Clinical News

First adaptive platform trial in ALS could speed development, find new biomarkers

An adaptive platform trial for ALS launched by Mass General could find new biomarkers to serve as surrogate endpoints or predictors of response in the pivotal trial and future studies. Researchers at Massachusetts General Hospital’s...
BC Week In Review | Sep 26, 2016
Clinical News

Pridopidine: Phase II data

Teva reported top-line data from the double-blind, international Phase II PRIDE-HD trial in 400 patients with HD showing that certain doses of oral pridopidine significantly improved disease progression as measured by total functional capacity (TFC)...
BC Extra | Sep 19, 2016
Clinical News

Teva HD candidate pridopidine heading for Phase III

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hopes to begin a Phase III program next year of pridopidine to treat Huntington's disease after seeing possible evidence of a disease-modifying effect in the exploratory Phase II PRIDE-HD study....
BioCentury | Sep 28, 2015

Serving nerves

Testimony at the first of FDA's patient-focused drug development meetings last week revealed that several programs in industry's pipeline for Huntington's disease are aligned with patient and caregiver desires for drugs that could halt progression...
BioCentury | Apr 6, 2015

Teva says I deu

The latest deal by Teva Pharmaceutical Industries Ltd. suggests the company has not changed course under new leadership, at least when it comes to building its CNS pipeline via business development. Last week, Teva said...
BC Week In Review | Oct 20, 2014
Company News

NeuroSearch neurology news

NeuroSearch appealed to the Eastern High Court of Denmark an August ruling from the City Court of Copenhagen ordering the company to pay a fine of DKK5 million ($851,000) for share price manipulation in violation...
BC Week In Review | May 5, 2014
Clinical News

Pridopidine: Phase II started

Teva began the double-blind, placebo-controlled, international Phase II PRIDE-HD trial to evaluate 45, 67.5, 90 and 112.5 mg oral pridopidine twice daily for 26 weeks in about 400 patients ages >=21 years with an onset...
Items per page:
1 - 10 of 98